Biotech Profile Chemistry Industry Life Sciences Branding & Creative Services 

Butler County Southwest Ohio

Butler County Alliance
Economic Development Dept of Butler County
130 High Street • 6th Floor • Hamilton, Ohio 45011
(513) 887-3413 / www.ButlerCounty.Biz

 

Economic Development Contact Us Press Room Site Consultant Downloads Request Info Home
 

 

BUTLER COUNTY, OHIO - BIOMED
State efforts to establish Ohio as a preferred destination for bioscience academia and industry have attracted 50 new or relocated businesses in 2005 alone. Ohio's bioscience entities generate more than $5.2 billion in direct economic impact and employ more than 37,000 skilled workers.

Key Industry Reports
Biotech Profile
Chemistry Industry
Life Sciences
 


Butler Tech plans to build first biomedical high school.  The Career School is looking to tap into Butler County’s medical boom.

 
 "This is a very important high technology investment for us," Commissioners president Greg Jolivette said.  "It validates Butler County as a site for biotechnology manufacturing and the quality of our workforce.  For the second time, Amylin has confirmed that they believe that we can provide them with the people that have the skill sets they require."

“Bioscience brings, highways, jobs, investment in research and medical breakthroughs that benefit the people of Ohio and people around the world,” Strickland told the gathering.
Governor Announces Support For Amylin Pharmaceuticals' Expanded Manufacturing Operation
Amylin expansion -  gives West Chester multi-million dollar boost!
 Amylin adding 500 jobs -  More invested in facility to make diabetes drug.
 Amylin building $400M facility in West Chester
 WEST CHESTER TWP. - Five hundred new jobs will be created through an expanded $400 million investment in a facility to produce a new diabetes drug being developed by Amylin Pharmaceuticals Inc., Gov. Ted Strickland confirmed Wednesday night. The jobs will pay an average of more than $50,000 annually.
 
 
Amylin buys $4.5 million in new West Chester Twp. land, eyes area for major expansion Top state officials in weekly contact with company executives, said state's lieutenant governor.
 
 

Drug firm welcomedto West Chester, Ohio
Technology startup capital has been concentrated on the coasts. But now that companies are increasingly looking to develop all of the major elements of a commercial enterprise -- not just research and development -- non-coastal areas will be able to better compete for biotech investment, Graham said. "Ohio has a very important orientation toward attracting businesses like ours to the economy," she said.
 
 
Butler County, Ohio beat out Northern Kentucky and three other states Thursday to lure Amylin Pharmaceuticals Inc. Candice Brooks cbrooks@coxohio.com  - The region’s qualified workforce and its close proximity to suppliers were two primary selling points that got the San Diego, Calif.-based company’s attention, said Reed Vickerman, vice president of corporate services for Amylin.  “Between Cincinnati and Dayton, there seems to be a hub or corridor developing of life sciences and high-tech expertise,” Vickerman said. “Plus, our partner Alkermes is in Wilmington and we wanted to be close to them.” Click here for complete story
 
 

Amylin Pharmaceuticals Selects Butler County, Ohio for Its $70 Million Biomedical Manufacturing Plant.  - Hamilton, OH, December 22, 2005 ­­­­-- Butler County Board of Commissioners president Chuck Furmon announced today that the Commissioners unanimously approved an eight-year, 75 percent Enterprise Zone tax abatement for Amylin Ohio LLC, a subsidiary of San Diego-based Amylin Pharmaceuticals.   Click here for complete story


 

Amylin Pharmaceuticals Acquires Facility in Ohio to Manufacture Exenatide LAR  - SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it has purchased an existing 150,000 square foot building and 26 acres of land in West Chester, Ohio. This acquisition completes previously announced facility expansion plans for the eventual commercial manufacturing of a long-acting release (LAR) formulation of exenatide, a product candidate in development for the treatment of type 2 diabetes. 
Click here for complete story

 

Amylin Pharmaceuticals at Port Union @ Union Centre
 Amylin Pharmaceuticals, a California-based biopharmaceutical company engaged in discovery, development and commercialization of innovative medicines for diabetes, obesity and cardiovascular disease, announced in December 2005 it will invest $70M to open a new biomedical manufacturing plant. The 151,200 square foot facility at 8814 Tradeport Drive in IDI's Port Union at Union Centre commerce park, will house Amylin's manufacturing and packaging operations for national and international distribution and will employee 200 at full production. www.amylin.com or www.idi.com.
 

 

Butler County Economic Development | Airports | Business Benefits | Communities | Demographics | Education | Employers | Healthcare | International Business | Location | Quality of Life | Sites & Facilities | Transportation | Workforce

Copyright © 2004 Butler County Ohio Economic Development All rights reserved.
130 High Street, 6th Floor
phone 513-887-3413, fax 513-785-5723
 e-mail info@ButlerCounty.biz 


 
 
 
 
 
Butler County Housing
 
Butler County Ohio
 
 

All information provided on the Butler County Alliance Economic Development official web site is provided for information purposes only. Although every reasonable effort is made to present current and accurate information, Butler County Alliance makes no guarantees of any kind. Information on this web site is subject to change without prior notice.

Any links to external web sites and/or non-Butler County Alliance Economic Development information provided on Butler County Alliance Economic Development web pages are provided as a courtesy. They should not be construed as an endorsement by Butler County Alliance Economic Development of the content or views of the linked materials.

In no event shall Butler County Alliance Economic Development be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content or services available on or through the Butler County Alliance Economic Development web site.

 

 

  Amylin Pharmaceuticals Selects Butler County, Ohio for Its $70 Million Biomedical Manufacturing Plant.
 		  
 

Amylin will establish a $70 million biomedical manufacturing facility in West Chester, Ohio to manufacture a long-acting release formulation of exenatide, a compound in development for type 2 diabetes.

Hamilton, OH, December 22, 2005 ­­­­-- Butler County Board of Commissioners president Chuck Furmon announced today that the Commissioners unanimously approved an eight-year, 75 percent Enterprise Zone tax abatement for Amylin Ohio LLC, a subsidiary of San Diego-based Amylin Pharmaceuticals.  Amylin will establish a $70 million biomedical manufacturing facility in West Chester, Ohio to manufacture a long-acting release formulation of exenatide, a compound in development for type 2 diabetes. 

“Amylin will create more than 50 jobs over a three-year period with an estimated payroll of more than $2.7 million.  That’s an average annual salary of over $52,000 per employee,” said Commissioner Mike Fox.  “These are the kind of well paying, high tech jobs that are important for Butler County’s continued growth to a knowledge-based economy.”

The facility will be located in an existing 151,200 sq. ft. building at 8814 Trade Port Drive in the Union Center Boulevard district of West Chester.  This project will begin in early January 2006, and will be completed in phases, allowing initial use of the facility before the final aspects of construction are completed in 2008.  Under the approved Enterprise Zone agreement, Amylin will receive tax benefits for making investments for the project

“This is a huge investment for Butler County in a new biomedical technology,” said Commissioner Greg Jolivette.  “I think that this is a testament to the quality of our workforce and validation by Amylin that they believe we can provide professionals with the skills that they require.”

Exenatide LAR, the long-acting release formulation of exenatide, is being developed for once-weekly administration.  BYETTA is the trade name for a formulation of exenatide that is approved by the Food and Drug Administration (FDA) for twice-daily use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels despite using commonly prescribed oral medications metformin, a sulfonylurea, or both.  Exenatide LAR has not been approved by the FDA for marketing in the United States. 

The exenatide LAR development program is a collaboration among Amylin; Alkermes of Cambridge, Massachusetts, which also has a facility in Wilmington, Ohio; and Eli Lilly and Company of Indianapolis, Indiana.

Back to Top